Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review

Bibliography

• Iressa (gefitinib) prescribing information. AstraZeneca; United Kingdom; 2005
   Google Scholar
• Teo YL, Ho HK, Chan A. Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis. Cancer Treat Rev 2013;39:199-206
   PubMed Web of Science ®Google Scholar
• Walgren JL, Mitchell MD, Thompson DC. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol 2005;35:325-61
   PubMed Web of Science ®Google Scholar
• Teng WC, Oh JW, New LS, et al. Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol 2010;78:693-703
   PubMed Web of Science ®Google Scholar
• Li X, Kamenecka TM, Cameron MD. Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities. Chem Res Toxicol 2009;22:1736-42
   PubMed Web of Science ®Google Scholar
• Li X, Kamenecka TM, Cameron MD. Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile. Drug Metab Dispos 2010;38:1238-45
   PubMed Web of Science ®Google Scholar
• Spraggs CF, Budde LR, Briley LP, et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 2011;29:667-73
   PubMed Web of Science ®Google Scholar
• Attia SM. Deleterious effects of reactive metabolites. Oxid Med Cell Longev 2010;3:238-53
   PubMed Web of Science ®Google Scholar
• Srivastava A, Maggs JL, Antoine DJ, et al. Role of reactive metabolites in drug-induced hepatotoxicity. Handb Exp Pharmacol 2010;196:165-94
   PubMedGoogle Scholar
• Ju C, Uetrecht JP. Mechanism of idiosyncratic drug reactions: reactive metabolites formation, protein binding and the regulation of the immune system. Curr Drug Metab 2002;3:367-77
   PubMedGoogle Scholar
• Pessayre D, Fromenty B, Berson A, et al. Central role of mitochondria in drug-induced liver injury. Drug Metab Rev 2012;44:34-87
   PubMed Web of Science ®Google Scholar
• Pessayre D, Berson A, Fromenty B. Features and mechanisms of drug-induced liver injury. In: Dykens JA, Will Y, editors. Drug-induced mitochondrial dysfunction. John Wiley & Sons, Inc; Hoboken, NJ, USA; 2008. p. 141-202
   Google Scholar
• Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003;349:474-85
   PubMed Web of Science ®Google Scholar
• Naisbitt DJ, Gordon SF, Pirmohamed M, Park BK. Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf 2000;23:483-507
   PubMed Web of Science ®Google Scholar
• Nelson SD. Molecular mechanisms of the hepatotoxicity caused by acetaminophen. Semin Liver Dis 1990;10:267-78
   PubMed Web of Science ®Google Scholar
• Beaune P, Dansette PM, Mansuy D. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci USA 1987;84:551-5
   PubMed Web of Science ®Google Scholar
• Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005;4:489-99
   PubMed Web of Science ®Google Scholar
• Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045
   PubMed Web of Science ®Google Scholar
• Kaplowitz N. Biochemical and cellular mechanisms of toxic liver injury. Semin Liver Dis 2002;22:137-44
   PubMed Web of Science ®Google Scholar
• Senior JR. Unintended hepatic adverse events associated with cancer chemotherapy. Toxicol Pathol 2010;38:142-7
   PubMed Web of Science ®Google Scholar
• Yu K, Geng X, Chen M, et al. High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury. Drug Metab Dispos 2014;42:744-50
   PubMed Web of Science ®Google Scholar
• Dahlin DC, Miwa GT, Lu AY, Nelson SD. N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen. Proc Natl Acad Sci USA 1984;81:1327-31
   PubMed Web of Science ®Google Scholar
• Guo GL, Moffit JS, Nicol CJ, et al. Enhanced acetaminophen toxicity by activation of the pregnane X receptor. Toxicol Sci 2004;82:374-80
   PubMed Web of Science ®Google Scholar
• Kenny JR, Mukadam S, Zhang C, et al. Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction. Pharm Res 2012;29:1960-76
   PubMed Web of Science ®Google Scholar
• Li X, He Y, Ruiz CH, et al. Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways. Drug Metab Dispos 2009;37:1242-50
   PubMed Web of Science ®Google Scholar
• Castellino S, O’Mara M, Koch K, et al. Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity. Drug Metab Dispos 2012;40:139-50
   PubMed Web of Science ®Google Scholar
• Takakusa H, Wahlin MD, Zhao C, et al. Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib. Drug Metab Dispos 2011;39:1022-30
   PubMed Web of Science ®Google Scholar
• Chan ECY, New LS, Chua TB, et al. Interaction of lapatinib with cytochrome P450 3A5. Drug Metab Dispos 2012;40:1414-22
   PubMed Web of Science ®Google Scholar
• Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010;51:615-20
   PubMed Web of Science ®Google Scholar
• Xu CF, Reck BH, Goodman VL, et al. Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. J Hepatol 2011;54:1237-43
   PubMed Web of Science ®Google Scholar
• Spraggs CF, Xu CF, Hunt CM. Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors. Pharmacogenomics 2013;14:541-54
   PubMed Web of Science ®Google Scholar
• Kaplowitz N. Drug-induced liver injury. Clin Infect Dis 2004;38:S44-8
   PubMed Web of Science ®Google Scholar
• Watkins PB. Idiosyncratic liver injury: challenges and approaches. Toxicol Pathol 2005;33:1-5
   PubMed Web of Science ®Google Scholar
• Watkins PB. Tacrine and transaminases. Alzheimer Dis Assoc Disord 1994;8:S32-8
   Web of Science ®Google Scholar
• Kunimasa K, Yoshioka H, Iwasaku M, et al. Successful treatment of non-small cell lung cancer with gefitinib after severe erlotinib-related hepatotoxicity. Intern Med J 2012;51:431-4
   Web of Science ®Google Scholar
• Nakatomi K, Nakamura Y, Tetsuya I, Kohno S. Treatment with gefitinib after erlotinib-induced liver injury: a case report. J Med Case Rep 2011;5:593
   PubMedGoogle Scholar
• Kijima T, Shimizu T, Nonen S, et al. Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism. J Clin Oncol 2011;29:e588-e90
   PubMed Web of Science ®Google Scholar
• Ku GY, Chopra A, Lopes GDL. Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity. Lung Cancer 2010;70:223-5
   PubMed Web of Science ®Google Scholar
• Nagano T, Kotani Y, Kobayashi K, et al. Successful erlotinib treatment for a patient with gefitinib-related hepatotoxicity and lung adenocarcinoma refractory to intermittently administered gefitinib. Case Rep Pulmonol 2011;2011:812972
   PubMedGoogle Scholar
• Takeda M, Okamoto I, Fukuoka M, Nakagawa K. Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity. J Clin Oncol 2010;28:e273-e74
   PubMed Web of Science ®Google Scholar
• Harbaum L, Marx A, Goekkurt E, et al. Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity. Int J Hematol 2014;99:91-4
   PubMed Web of Science ®Google Scholar
• Shah RR, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf 2013;36:491-503
   PubMed Web of Science ®Google Scholar
• Chen J, Gu R, Wang Q, et al. Gefitinib-induced hepatotoxicity in patients treated for non-small cell lung cancer. Onkologie 2012;35:509-13
   PubMed Web of Science ®Google Scholar
• Seki N, Uematsu K, Shibakuki R, Eguchi K. Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration. J Clin Oncol 2006;24:3213-14; author reply 14-15
   PubMed Web of Science ®Google Scholar
• Ferrero D, Pogliani EM, Rege-Cambrin G, et al. Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematologica 2006;91:ECR27
   PubMedGoogle Scholar
• Aliberti S, Grignani G, Allione P, et al. An acute hepatitis resembling autoimmune hepatitis occurring during imatinib therapy in a gastrointestinal stromal tumor patient. Am J Clin Oncol 2009;32:640-1
   PubMed Web of Science ®Google Scholar
• Dhalluin-Venier V, Besson C, Dimet S, et al. Imatinib mesylate-induced acute hepatitis with autoimmune features. Eur J Gastroenterol Hepatol 2006;18:1235-7
   PubMed Web of Science ®Google Scholar
• Gupta S, Bhatt VR, Varma S. Recurrent imatinib-induced hepatotoxicity in a chronic myeloid leukaemia patient successfully managed with prednisone. BMJ Case Rep 2011;2011. 10.1136/bcr.11.2010.3516
   Google Scholar
• Ikuta K, Torimoto Y, Jimbo J, et al. Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management. Int J Hematol 2005;82:343-6
   PubMed Web of Science ®Google Scholar
• Al Sobhi E, Zahrani Z, Zevallos E, Zuraiki A. Imatinib-induced immune hepatitis: case report and literature review. Hematology (Am Soc Hematol Educ Program) 2007;12:49-53
   Google Scholar
• Yamazaki R, Okamoto S, Chen CK, et al. Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase. Leuk Lymphoma 2006;47:1427-30
   PubMed Web of Science ®Google Scholar
• Uetrecht JP. New concepts in immunology relevant to idiosyncratic drug reactions: the ‘danger hypothesis’ and innate immune system. Chem Res Toxicol 1999;12:387-95
   PubMed Web of Science ®Google Scholar
• Teo YL, Saetaew M, Chanthawong S, et al. Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence. Breast Cancer Res Treat 2012;133:703-11
   PubMed Web of Science ®Google Scholar
• Spataro V. Nilotinib in a patient with postnecrotic liver cirrhosis related to imatinib. J Clin Oncol 2011;29:e50-2
   PubMed Web of Science ®Google Scholar
• Pariente A, Etcharry F, Cales V, et al. Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour. Eur J Gastroenterol Hepatol 2006;18:785-7
   PubMed Web of Science ®Google Scholar
• Tonyali O, Coskun U, Yildiz R, et al. Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors. Med Oncol 2010;27:768-73
   PubMed Web of Science ®Google Scholar
• Westgeest HM, Van Erp NP, Honeywell RJ, et al. Successful treatment of renal cell carcinoma with sorafenib after effective but hepatotoxic sunitinib exposure. J Clin Oncol 2013;31:e83-6
   PubMed Web of Science ®Google Scholar
• Kong JH, Yoo SH, Lee KE, et al. Early imatinib mesylate-induced hepatotoxicity in chronic myelogenous leukaemia. Acta Haematol 2007;118:205-8
   PubMed Web of Science ®Google Scholar
• Lai YC, Lin PC, Lai JI, et al. Successful treatment of erlotinib-induced acute hepatitis and acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review. Int J Clin Pharmacol Ther 2011;49:461-6
   PubMed Web of Science ®Google Scholar